Ceftolozane/tazobactam: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
(Add References) |
||
| Line 37: | Line 37: | ||
*Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis | *Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis | ||
*Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases | *Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases | ||
==References== | |||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 09:38, 22 March 2026
General
- Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination)
- Dosage Forms: IV
- Common Trade Names: Zerbaxa
Adult Dosing
- 1.5 grams (1gm ceftolozane/0.5gm tazobactam) IV q8H
Pediatric Dosing
Safety/efficacy not established in children
Special Populations
- Pregnancy Rating: B
- Lactation: Infant risk cannot be ruled out
- Renal Dosing: 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment
- Hepatic Dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- C. difficile diarrhea
- Renal impairment
- Hypersensitivity
Common
- Nausea, diarrhea
- Headache
- Fever
Pharmacology
- Half-life: Ceftolozane- ~3h, Tazobactam- ~1h
- Metabolism: N/A
- Excretion: Renal (100%)
Mechanism of Action
- Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis
- Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases